Moderna (NASDAQ:MRNA) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Moderna (NASDAQ:MRNA) in a research report sent to investors on Friday,Benzinga reports.

Several other research firms also recently issued reports on MRNA. Barclays decreased their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research note on Monday, September 16th. Leerink Partners decreased their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Bank of America decreased their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $93.18.

Moderna Trading Down 6.9 %

Moderna stock traded down $3.45 during trading on Friday, reaching $46.83. The company had a trading volume of 13,561,538 shares, compared to its average volume of 4,882,079. Moderna has a 12-month low of $46.57 and a 12-month high of $170.47. The stock’s 50 day moving average price is $61.85 and its two-hundred day moving average price is $99.22. The firm has a market capitalization of $18.00 billion, a price-to-earnings ratio of -3.04 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the firm earned ($1.39) earnings per share. Moderna’s revenue was up 3.8% compared to the same quarter last year. As a group, equities analysts expect that Moderna will post -9.89 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,184 shares of company stock worth $238,531. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after buying an additional 5,129,800 shares during the period. Capital World Investors increased its stake in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after buying an additional 18,728 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Dimensional Fund Advisors LP increased its stake in Moderna by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after buying an additional 29,566 shares during the period. Finally, ARK Investment Management LLC increased its stake in Moderna by 10.4% during the 3rd quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after buying an additional 109,852 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.